Milestone Pharmaceuticals

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing innovative small molecule therapeutics for cardiovascular diseases. The company primarily targets conditions such as paroxysmal supraventricular tachycardia (PSVT) with its lead product candidate, Etripamil, a novel calcium channel blocker. Milestone operates in the biopharmaceutical market, serving patients and healthcare providers who require effective treatments for acute cardiovascular conditions. The business model is centered around research and development, clinical trials, and eventual commercialization of its drug candidates. Revenue is generated through product sales, partnerships, and potential licensing agreements. The company employs a lean and cost-efficient operational model, minimizing overhead and focusing resources on key development programs.